Literature DB >> 26192360

Immunogenicity of porcine P[6], P[7]-specific △VP8* rotavirus subunit vaccines with a tetanus toxoid universal T cell epitope.

Xiaobo Wen1, Xiaoman Wei2, Xuhua Ran3, Hongbo Ni1, Si Cao1, Yao Zhang1.   

Abstract

Currently, commercial porcine rotavirus vaccines remain varied limitations. The objective of this study is to develop an alternative porcine rotavirus subunit vaccine candidate by parenteral administration, which enables to elicit robust immune responses against most prevalence porcine rotavirus strains. The bacterially-expressed porcine rotavirus P[6]- or P[7]-specific truncated VP8* (aa 64-223) recombinant protein with or without a universal tetanus toxoid CD4(+) T cell epitope P2 was generated. All the recombinant subunit proteins △VP8*s or P2-△VP8*s were of high solubility and high yields. The immunogenicity of each purified △VP8* and P2-△VP8* was evaluated in mice (10 μg/dose) or guinea pigs (20 μg/dose) immunized IM with 600 μg aluminum hydroxide three times at 2-week interval. The introduction of P2T cell epitope to P[7]-△VP8* elicited significantly higher IgG titer in mice than its absence. Comparatively, P2 epitope slightly enhanced the immunogenicity of P[6]-△VP8*. P2-P[7]△VP8* elicited high titer of neutralizing antibody against heterotypic P[7]-specific rotaviruses with varied G type combination. Our data indicated that two subunit vaccines could be plausible bivalent rotavirus vaccine candidate to provide antigenic coverage of porcine rotavirus strains of global or regional importance.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  P type; Porcine rotavirus; Subunit vaccine; T cell epitope; Tetanus toxoid; VP8* protein

Mesh:

Substances:

Year:  2015        PMID: 26192360     DOI: 10.1016/j.vaccine.2015.07.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Longitudinal Surveillance of Porcine Rotavirus B Strains from the United States and Canada and In Silico Identification of Antigenically Important Sites.

Authors:  Frances K Shepherd; Michael P Murtaugh; Fangzhou Chen; Marie R Culhane; Douglas G Marthaler
Journal:  Pathogens       Date:  2017-12-03

2.  Formulation and preclinical studies with a trivalent rotavirus P2-VP8 subunit vaccine.

Authors:  Kyle Lakatos; David McAdams; Jessica A White; Dexiang Chen
Journal:  Hum Vaccin Immunother       Date:  2020-01-29       Impact factor: 3.452

3.  Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency.

Authors:  David McAdams; Marcus Estrada; David Holland; Jasneet Singh; Nishant Sawant; John M Hickey; Prashant Kumar; Brian Plikaytis; Sangeeta B Joshi; David B Volkin; Robert Sitrin; Stan Cryz; Jessica A White
Journal:  Vaccine       Date:  2022-07-22       Impact factor: 4.169

4.  Surface Display of Antigen Protein VP8* of Porcine Rotavirus on Bacillus Subtilis Spores Using CotB as a Fusion Partner.

Authors:  Wanqiang Li; Jie Feng; Jiajun Li; Jianzhen Li; Zhenhua Wang; Abdul Khalique; Miao Yang; Xueqin Ni; Dong Zeng; Dongmei Zhang; Bo Jing; Qihui Luo; Kangcheng Pan
Journal:  Molecules       Date:  2019-10-22       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.